284 related articles for article (PubMed ID: 30417561)
1. Recent Advances in the Design and Development of Non-nucleoside Reverse Transcriptase Inhibitor Scaffolds.
Shirvani P; Fassihi A; Saghaie L
ChemMedChem; 2019 Jan; 14(1):52-77. PubMed ID: 30417561
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Yu M; Fan E; Wu J; Liu X
Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919
[TBL] [Abstract][Full Text] [Related]
3. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
4. The effect of NNRTIs on HIV reverse transcriptase dimerization.
Tachedjian G; Goff SP
Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
[TBL] [Abstract][Full Text] [Related]
5. Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
La Regina G; Coluccia A; Silvestri R
Antivir Chem Chemother; 2010 Aug; 20(6):213-37. PubMed ID: 20710063
[TBL] [Abstract][Full Text] [Related]
6. Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains.
Yu F; Li W; Wang L; Dai Y; Lu X; Wang Q; Xie L; Jiang S
Molecules; 2018 Jul; 23(7):. PubMed ID: 30004408
[TBL] [Abstract][Full Text] [Related]
7. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
8. New non-nucleoside reverse transcriptase inhibitors (NNRTIs) in development for the treatment of HIV infections.
Pauwels R
Curr Opin Pharmacol; 2004 Oct; 4(5):437-46. PubMed ID: 15351347
[TBL] [Abstract][Full Text] [Related]
9. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif.
Li W; Li X; De Clercq E; Zhan P; Liu X
Eur J Med Chem; 2015 Sep; 102():167-79. PubMed ID: 26276432
[TBL] [Abstract][Full Text] [Related]
10. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation and molecular modeling studies of new 2,3-diheteroaryl thiazolidin-4-ones as NNRTIs.
Debnath U; Verma S; Singh P; Rawat K; Gupta SK; Tripathi RK; Siddiqui HH; Katti SB; Prabhakar YS
Chem Biol Drug Des; 2015 Nov; 86(5):1285-91. PubMed ID: 26031778
[TBL] [Abstract][Full Text] [Related]
12. Recent progress in HIV-1 inhibitors targeting the entrance channel of HIV-1 non-nucleoside reverse transcriptase inhibitor binding pocket.
Gu SX; Xiao T; Zhu YY; Liu GY; Chen FE
Eur J Med Chem; 2019 Jul; 174():277-291. PubMed ID: 31051402
[TBL] [Abstract][Full Text] [Related]
13. Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928).
Li X; Gao P; Zhan P; Liu X
Expert Opin Ther Pat; 2016 May; 26(5):629-35. PubMed ID: 26742549
[TBL] [Abstract][Full Text] [Related]
14. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update.
Song Y; Fang Z; Zhan P; Liu X
Curr Med Chem; 2014; 21(3):329-55. PubMed ID: 24164196
[TBL] [Abstract][Full Text] [Related]
16. Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Zeng ZS; He QQ; Liang YH; Feng XQ; Chen FE; De Clercq E; Balzarini J; Pannecouque C
Bioorg Med Chem; 2010 Jul; 18(14):5039-47. PubMed ID: 20598556
[TBL] [Abstract][Full Text] [Related]
17. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase.
Sweeney ZK; Harris SF; Arora SF; Javanbakht H; Li Y; Fretland J; Davidson JP; Billedeau JR; Gleason SK; Hirschfeld D; Kennedy-Smith JJ; Mirzadegan T; Roetz R; Smith M; Sperry S; Suh JM; Wu J; Tsing S; Villaseñor AG; Paul A; Su G; Heilek G; Hang JQ; Zhou AS; Jernelius JA; Zhang FJ; Klumpp K
J Med Chem; 2008 Dec; 51(23):7449-58. PubMed ID: 19007201
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update.
Zhan P; Liu X; Li Z
Curr Med Chem; 2009; 16(22):2876-89. PubMed ID: 19689270
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-
Yang Y; Kang D; Nguyen LA; Smithline ZB; Pannecouque C; Zhan P; Liu X; Steitz TA
Elife; 2018 Jul; 7():. PubMed ID: 30044217
[TBL] [Abstract][Full Text] [Related]
20. Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors.
Santos LH; Ferreira RS; Caffarena ER
Mem Inst Oswaldo Cruz; 2015 Nov; 110(7):847-64. PubMed ID: 26560977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
